echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > Modification of "molecular glue" can develop new anti-tumor drugs

    Modification of "molecular glue" can develop new anti-tumor drugs

    • Last Update: 2021-11-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Modification of "molecular glue" can develop new anti-tumor drugs
    Modification of "molecular glue" can develop new anti-tumor drugs.


    During the development of the human embryo, the web between the fingers will gradually disappear; during the growth of the tadpole, the tail will gradually disappear
    .


    In the process of growth and development, this "disappearance" is a kind of gene-regulated cell death, also known as apoptosis, which is a normal life phenomenon


    However, tumor cells have broken the balance between proliferation and death due to defects in the apoptosis mechanism and become "immortal" cells
    .


    Therefore, an effective strategy to treat tumors is to use chemical drugs or gene regulation to induce tumor cell apoptosis


    On October 27th, Wang Xiaodong’s team, director of the Beijing Institute of Life Sciences, Wang Hongwei’s team, professor of the Advanced Innovation Center for Structural Biology, Tsinghua University, and the Huang Niu team and Qi Xiangbing’s team worked together to publish a paper in Nature Communications, analyzing the three structures Different small molecule compounds (anagrelide, nauclefine, DNMDP) process the structure of the PDE3A-SLFN12 complex under the conditions to obtain the key structure information of the interaction between the small molecule and the protein complex
    .

    "Three small molecules can make the two proteins PDE3A and SLFN12 form a complex
    .


    Once the PDE3A-SLFN12 complex is formed, the cell will undergo apoptosis


    Based on the obtained PDE3A-SLFN12 complex structure model and small molecule binding mode, the researchers selected anagrelide, a kind of treatment for thrombocytosis, which has good clinical pharmacokinetics, pharmacodynamics and safety.
    Listed drugs) as the target molecule, carry out computer simulation and further optimization and transformation
    .


    The results show that the modified anagrelide analogs have a higher activity in inducing cell apoptosis and have a stronger potential to inhibit tumor growth in mouse tumor formation model experiments


    Small molecule compounds of different structures can bind to PDE3A because the substrate binding region of the protein can accommodate chemical groups with different structures
    .


    Whether these small molecule compounds activate or inhibit cell apoptosis depends on whether the molecule has the properties of a molecular glue that can bind to SLFN12 to "stick" PDE3A and SLFN12 together


    "We use biochemistry, structural biology, computational biology and chemical biology to design and optimize molecular glue based on the structure of the complex, and create more effective apoptosis-inducing molecules, which lays the foundation for the development of new tumor therapeutic drugs.
    the foundation
    .


    "Wang Hongwei, said," this work is a collaboration of four teams each from a different point of view of research results, are indispensable


    Related paper information: https://doi.


    https://doi.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.